Pandemic fears force Chinese biotech to postpone Hong Kong IPO meetings — Bloomberg

At the same time the coronavirus outbreak originating from Wuhan is boosting shares prices of a raft of (mostly overseas) drugmakers, it appears to have also forced at least one domestic biotech to slow down its IPO plans in Hong Kong.